Global Retinal Vein Occlusion Market to Grow at a 16.04% CAGR of by 2018 Says a New Research Report at

Dallas, Texas (PRWEB) August 07, 2014

One of the growth-pertaining trends in the market is the introduction of biologics as a treatment option for retinal vein occlusion. Drugs such as Avastin (bevacizumab) and Lucentis (ranibizumab), which are Vascular Endothelial Growth Factor (VEGF) inhibitors, are being used in the treatment of retinal vein occlusion in patients. This is expected to drive the growth of the market in the forecast period.

Analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018. According to the report, high unmet needs because of the presence of fewer approved treatment options for this indication are one of the major drivers of the market. There are only three drugs approved for the indication: Eylea, by Bayer and Regeneron Pharmaceuticals; Lucentis, by F. Hoffmann-La Roche and Novartis; and Ozurdex, by Allergan. Therefore, the launch of new products for the treatment of retinal vein occlusion is expected to drive the market.

Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.

Purchase Report @

Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Global Retinal Vein Occlusion Market: Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc.

Other prominent vendors in the market are: Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals.

Further, the report states that one of the major challenges that the market faces is the serious adverse side effects associated with the drugs used to treat retinal vein occlusion. Some of the major side effects include increases in ocular pressure, glaucoma, conjunctival hemorrhage, cataract, headache, vitreous detachment, eye pain, endophthalmitis, eye redness, and specks in the vision. This lowers the acceptability of these drugs among patients and medical fraternities.

Key Regions

This entry was posted in Online Marketing and tagged , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply